If you are:
Not Recommended: INCR RISK OF NEURAL TUBE DEFECTS AND LOWER IQ, CONSIDER MATERNAL TX BENEFIT
Precaution: LIMITED DATA SUGGEST MINIMAL AMNT EXCRETED;MONITOR INFANT FOR ADVERSE EFFECTS
An adult over 60:
management or monitoring precaution: Hepatic-Elderly may have slower metabolism and protein binding which requires dosage reduction. Monitor closely. Neuro/Psych-Use caution in elderly with a history of recurrent falls. Drug may produce somnolence, ataxia, impaired psychomotor function, syncope, and additional falls. Monitor fluid and nutritional intake and avoid dehydration. Musculoskeletal-Postmarketing reports of fractures, decreased bone mineral density, osteopenia, osteoporosis.
Giving Depakene to a child under 12:
management or monitoring precaution: Fatal hepatotoxicity risk in young children with mitochondrial disease associated with POLG gene mutation and on multiple anticonvulsants. Monitor closely for liver impairment including non-specific symptoms (e.g., lethargy, facial edema,vomiting. Rare risk of severe pancreatitis.
Severe Precaution: Risk of serious or fatal hepatotoxicity in age <2 years especially with multiple anticonvulsants, and mitochondrial disease associated with POLG gene mutation. Use as single agent and monitor closely for liver impairment, including non-specific symptoms (e.g., lethargy, facial edema,vomiting).